<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Microbiology and antibiotic management of chronic rhinosinusitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Microbiology and antibiotic management of chronic rhinosinusitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Microbiology and antibiotic management of chronic rhinosinusitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Itzhak Brook, MD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic rhinosinusitis (CRS) is defined as a complex inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer despite attempts at medical management. The diagnostic criteria for CRS are discussed separately. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Diagnosis'</a>.)</p><p>Factors that may contribute to the development of CRS include exposure to allergens and irritants, defects in mucociliary function, immunodeficiency, obstruction of sinus outflow (eg, polyps), and infections with bacteria, viruses, and fungi. The common endpoint is local inflammation and swelling of the sinonasal mucosa and impairment of normal sinus drainage. The recognition that CRS represents a multifactorial inflammatory disorder, rather than a persistent bacterial infection, has led to the reexamination of the role of antimicrobials in CRS. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p>The medical management of CRS is focused upon controlling the inflammation that predisposes patients to obstruction, thus minimizing the incidence of superinfections. Despite this, many forms of CRS are associated with poor sinus drainage and secondary bacterial infections. Most patients require antibiotics to clear infection at the outset of therapy and intermittently thereafter to treat acute exacerbations of CRS. However, the role of these agents beyond these two indications remains an area of investigation. </p><p>This topic will review the evolution of the upper respiratory flora in rhinosinusitis as well as the microbiology of and antibiotic selection for CRS. The overall approach to management of CRS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>Acute rhinosinusitis, allergic rhinitis, and fungal sinusitis are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7530.html" rel="external">"Pathogenesis of allergic rhinitis (rhinosinusitis)"</a> and  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a> and  <a class="medical medical_review" href="/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H2561585346"><span class="h2">Bacterial flora of non-inflamed sinuses</span><span class="headingEndMark"> — </span>The uninfected "normal" sinuses contain aerobic and anaerobic bacterial flora similar to those present in acute and chronic sinusitis [<a href="#rid1">1</a>]. </p><p>Bacterial flora in the normal non-inflamed sinus has been delineated in studies utilizing bacterial cultures [<a href="#rid1">1</a>] and molecular methodologies [<a href="#rid2">2</a>]. In a study that evaluated the impact of the microbiota on predictors of disease outcomes, 26 control subjects had similar biodiversity as 56 patients with chronic rhinosinusitis (CRS) [<a href="#rid3">3</a>]. Among the CRS subtypes examined, only purulence and the comorbid condition of asthma were associated with alterations in microbial community composition. Among 27 patients with CRS who were followed postoperatively, better outcomes were associated with more diverse bacterial communities present at the time of surgery, along with higher relative abundances of <em>Actinobacteria</em>.</p><p>Other data suggest that the host response or lack of response to the normal sinus flora may be key to the development of sinus inflammation [<a href="#rid4">4</a>]. The number of organisms [<a href="#rid4">4</a>] and the likelihood of biofilm formation [<a href="#rid5">5</a>] are higher in chronic sinusitis than in uninfected sinuses. Microbial biofilms seem to play an active role in the pathogenesis of CRS. They represent an adaptive defense resource enabling resistance to antibiotics and host defense mechanisms. Biofilms are thought to be accountable for refractory cases of sinusitis by perpetuating local inflammation [<a href="#rid6">6</a>]. These observations may help to explain the chain of events that lead to inflammation in CRS.</p><p class="headingAnchor" id="H3"><span class="h2">Evolution of bacterial flora</span><span class="headingEndMark"> — </span>The microbiology of rhinosinusitis evolves through several phases. The early phase (acute rhinosinusitis) is usually caused by a viral infection (most commonly rhinovirus, adenovirus, influenza, or parainfluenza) that generally lasts up to 10 days; complete recovery occurs in 99 percent of patients [<a href="#rid7">7</a>]. In occasional patients, a secondary acute bacterial infection develops. The most common bacterial causes of acute rhinosinusitis are aerobes such as <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, and <em>Moraxella catarrhalis</em>. (See  <a class="medical medical_review" href="/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p>If resolution from acute rhinosinusitis does not occur, colonizing anaerobic oropharyngeal flora and aerobes, such as <em>Staphylococcus aureus</em>, become predominant over time [<a href="#rid8">8-17</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Anaerobes</span><span class="headingEndMark"> — </span>Anaerobes are prominent in the sinuses of both children [<a href="#rid10">10,18,19</a>] and adults [<a href="#rid11">11-14,16,17,20-26</a>] with chronic rhinosinusitis. As an example, in one study, middle meatal specimens from patients with CRS without nasal polyps had anaerobic bacterial enrichment and lower microbiome diversity compared with healthy subjects, patients with acute rhinosinusitis, and patients with CRS with nasal polyps [<a href="#rid27">27</a>]. Similarly, in a series of five patients with acute maxillary rhinosinusitis who did not respond to therapy and underwent repeated endoscopic aspirations of sinus secretions, growth of resistant anaerobes occurred over time, including <em>Fusobacterium nucleatum</em>, pigmented <em>Prevotella</em> spp, <em>Porphyromonas </em>spp, and <em>Peptostreptococcus </em>spp [<a href="#rid26">26</a>]. Elevated immunoglobulin G (IgG) antibodies against <em>Fusobacterium</em> and <em>Prevotella</em> spp have also been described in patients with chronic sinusitis [<a href="#rid28">28</a>].</p><p>Several factors may contribute to the emergence of anaerobes:</p><p class="bulletIndent1"><span class="glyph">●</span>Selective pressure of antimicrobial agents that enable resistant organisms to survive.</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal inflammation and edema decrease the blood supply to the sinuses, which leads to reduced oxygen tension [<a href="#rid29">29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Aerobic bacteria consume oxygen and decrease the pH of the sinuses, which promotes the growth of anaerobes [<a href="#rid30">30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Expression of some anaerobic virulence factors, such as a capsule, is slow [<a href="#rid31">31,32</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Aerobes</span><span class="headingEndMark"> — </span>Aerobic gram-negative bacilli and <em>S. aureus</em> (including methicillin-resistant <em>S. aureus </em>[MRSA]) have also been implicated in CRS. Polymicrobial infection is common and may be synergistic [<a href="#rid32">32</a>].</p><p>Aerobes (in the absence of anaerobes) have been implicated in the pathogenesis of CRS. Most studies in which only aerobes were cultured from CRS patients did not use sufficiently careful techniques for the recovery of anaerobes; however, even carefully performed studies sometimes fail to identify anaerobes [<a href="#rid33">33</a>]. Thus, it is possible that some patients with CRS have a predominance of aerobes or a mixture of aerobes and anaerobes.</p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative bacilli – Aerobic gram-negative bacilli, such as <em>Pseudomonas aeruginosa</em>, <em>Klebsiella pneumoniae</em>, <em>Proteus mirabilis</em>, <em>Enterobacter </em>spp, and <em>Escherichia coli</em>, have been implicated as etiologic agents of CRS, especially in patients with underlying conditions such as cystic fibrosis (in the case of <em>Pseudomonas</em>) diabetes mellitus, and immunocompromising conditions (eg, stem cell transplant, neutropenia, or advanced human immunodeficiency virus [HIV]) [<a href="#rid34">34-38</a>].</p><p></p><p class="bulletIndent1">Since these gram-negative bacilli are rarely found in cultures of the middle meatus obtained from normal individuals, their isolation from symptomatic patients suggests a pathogenic role. However, their presence could also be due to selection pressure following administration of antimicrobial therapy. In one study, aerobic gram-negative bacilli were recovered more often in patients who had had previous surgery or sinus irrigation [<a href="#rid35">35</a>]. <em>P. aeruginosa</em> was also more common in patients receiving systemic steroids. Other studies have also noted this shift toward gram-negative organisms in patients who have been extensively and repeatedly treated with antibiotics or have undergone sinus surgery [<a href="#rid36">36,39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Staphylococcus aureus</em> – <em>S. aureus</em> colonizes the nasal mucosa of 20 to 30 percent of normal individuals and is found more frequently in patients with rhinosinusitis, especially in those with CRS. In the United States, the incidence of MRSA specifically may be increasing as both a nasal colonizer and a cause of rhinosinusitis [<a href="#rid41">41-44</a>]. Some [<a href="#rid45">45</a>] but not all [<a href="#rid46">46</a>] studies suggest that patients with diabetes mellitus have a higher likelihood of nasal colonization with <em>S. aureus</em>. </p><p></p><p>Coagulase-negative staphylococci are normal nasal colonizers and are not thought to be pathogenic in sinusitis or other respiratory infections [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Specific clinical settings</span></p><p class="headingAnchor" id="H7"><span class="h3">Nasal polyposis</span><span class="headingEndMark"> — </span>Studies of the microbiology of infections in patients with CRS with nasal polyposis suggest that the organisms involved are similar to those in CRS without nasal polyposis [<a href="#rid48">48-50</a>]. CRS with and without nasal polyposis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Acute exacerbation of chronic rhinosinusitis</span><span class="headingEndMark"> — </span>Acute exacerbation of CRS (AECRS) represents a sudden worsening of the baseline manifestations of CRS, which may involve new symptoms or an accentuation of existing symptoms. The acute, but not the chronic, symptoms typically resolve completely between occurrences. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p>The microbiology of AECRS includes <em>H. influenzae</em>, <em>S. pneumoniae</em>, and <em>M. catarrhalis</em>, in addition to the organisms potentially associated with CRS (ie, anaerobes, <em>S. aureus</em>, and gram-negative bacilli). (See <a class="local">'Evolution of bacterial flora'</a> above.)</p><p>This was demonstrated in a study in which serial endoscopic aspirations were performed in seven patients who had ≥3 episodes of maxillary AECRS per year, each lasting ≥10 days, with complete resolution of their acute symptoms between episodes [<a href="#rid51">51</a>]. The patients were followed over a period of 125 to 242 days.</p><p>Two to four bacterial isolates were recovered from each sample. The aerobes isolated were <em>H. influenzae</em>, <em>S. pneumoniae</em>, <em>M. catarrhalis</em>, <em>S. aureus</em>, and <em>K. pneumoniae</em>, while the anaerobes included pigmented <em>Prevotella</em> spp, <em>Porphyromonas </em>spp, <em>Peptostreptococcus</em> spp, <em>Fusobacterium</em> spp, and <em>Cutibacterium acnes</em>. Sequential cultures over time noted changes in species isolated as well as increased antimicrobial resistance.</p><p class="headingAnchor" id="H9"><span class="h3">Odontogenic sinusitis</span><span class="headingEndMark"> — </span>Odontogenic sinusitis is a well-recognized entity and accounts for approximately 10 to 12 percent of cases of maxillary sinusitis [<a href="#rid52">52</a>] and may be either acute or chronic [<a href="#rid53">53</a>]. The microorganisms recovered from odontogenic infections generally reflect the oral flora (eg, anaerobes and streptococci). (See  <a class="medical medical_review" href="/d/html/3417.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections"</a>.)</p><p>The association between periapical abscesses and rhinosinusitis was established in a study of pus aspirates from five periapical abscesses of the upper jaw and their corresponding maxillary sinuses [<a href="#rid54">54</a>]. A polymicrobial flora was found in all instances, and the number of isolates grown from each specimen ranged from two to five. Anaerobes were recovered from all specimens. The predominant anaerobes grown were <em>Prevotella</em> spp, <em>Porphyromonas</em> spp, <em>Peptostreptococcus</em> spp, and <em>F. nucleatum</em>. Concordance in the microbiologic findings between periapical abscess and the maxillary sinus flora was found in all instances, suggesting contiguous spread.</p><p>Another study evaluated the microbiology of 20 patients with acute rhinosinusitis and 28 patients with chronic maxillary sinusitis associated with odontogenic infection [<a href="#rid37">37</a>]. Polymicrobial infection was common, with an average of 3.4 isolates recovered per specimen. A total of 98 isolates were recovered from the 28 cases of CRS: 21 aerobic and facultative and 77 anaerobic. Aerobes alone were recovered in 3 (11 percent), anaerobes only in 11 (39 percent), and mixed aerobic and anaerobic bacteria in 14 (50 percent). The predominant anaerobes in both acute and chronic infection were <em>Peptostreptococcus</em> spp, <em>Fusobacterium</em> spp, and pigmented <em>Prevotella</em> and <em>Porphyromonas</em> spp, all members of the oropharyngeal flora that predominate in periodontal and endodontal infection. The most commonly isolated aerobes were alpha-hemolytic streptococci, microaerophilic streptococci, and <em>S. aureus</em>.</p><p class="headingAnchor" id="H10"><span class="h3">Concurrent chronic otitis media in children</span><span class="headingEndMark"> — </span>One study correlated the microbiology of concurrent chronic otitis media with effusion and maxillary sinusitis in 32 children [<a href="#rid18">18</a>]. Two-thirds of the patients had a bacterial etiology. The most common isolates were <em>H. influenzae</em> (nine isolates), <em>S. pneumoniae</em> (seven isolates), <em>Prevotella </em>spp (eight isolates), and <em>Peptostreptococcus</em> spp (six isolates). Microbiologic concordance between the ear and sinus was found in 22 (69 percent) culture-positive patients.</p><p class="headingAnchor" id="H11"><span class="h3">Immunocompromised hosts</span><span class="headingEndMark"> — </span>Rhinosinusitis occurs in a range of immunocompromised hosts including those with neutropenia, diabetes mellitus, critical illness, or HIV, and may be either acute or chronic [<a href="#rid38">38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with neutropenia, fungi and <em>P. aeruginosa</em> are the most common causes of rhinosinusitis [<a href="#rid38">38,55</a>]. When fungal rhinosinusitis is present, <em>Aspergillus</em> spp are frequently the causative organism, although Zygomycetes (eg, <em>Mucor</em>, <em>Rhizopus</em>), <em>Alternaria</em>, and other molds have been implicated [<a href="#rid55">55</a>]. Hematologic malignancy is another risk factor for invasive fungal rhinosinusitis. (See  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with diabetes mellitus, <em>P. aeruginosa</em> and other gram-negative bacilli have been isolated from intraoperative sinus cultures more frequently than in patients without diabetes mellitus, although data are limited [<a href="#rid46">46</a>]. Diabetes mellitus has also been associated with fungal rhinosinusitis. (See  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with cystic fibrosis, <em>P. aeruginosa</em> often causes rhinosinusitis [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with HIV, sinusitis often presents with non-specific symptoms and is refractory to treatment [<a href="#rid56">56</a>]. Causes of rhinosinusitis may include common and uncommon organisms, such as <em>S. aureus</em>, streptococci, anaerobes, <em>P. aeruginosa</em>, and fungi (<em>Aspergillus</em>, <em>Cryptococcus</em>, and <em>Rhizopus</em>) [<a href="#rid38">38,57</a>]. Most studies reporting on the microbiology of rhinosinusitis in patients with HIV, however, are from over 20 years ago and include mainly patients with low CD4 cell counts, so the findings may not be generalizable to patients with well-controlled HIV. Rare causes of rhinosinusitis in patients with acquired immunodeficiency syndrome (AIDS) include cytomegalovirus; nontuberculous mycobacteria, such as <em>Mycobacterium kansasii</em>; and parasites, such as <em>Microsporidium</em>, <em>Cryptosporidium</em>, and <em>Acanthamoeba</em> [<a href="#rid38">38,58,59</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Complications of CRS, such as orbital cellulitis, brain abscess, subdural empyema, and epidural abscess are often polymicrobial and include both aerobes and anaerobes [<a href="#rid15">15,60,61</a>]. These infections are discussed separately. (See  <a class="medical medical_review" href="/d/html/3414.html" rel="external">"Orbital cellulitis"</a> and  <a class="medical medical_review" href="/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a> and  <a class="medical medical_review" href="/d/html/1279.html" rel="external">"Treatment and prognosis of bacterial brain abscess"</a> and  <a class="medical medical_review" href="/d/html/103898.html" rel="external">"Intracranial epidural abscess"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Fungi</span><span class="headingEndMark"> — </span>Fungi may cause allergic fungal rhinosinusitis, fungal colonization, or invasive fungal sinusitis. Allergic fungal rhinosinusitis refers to CRS that is accompanied by sinus opacification with "allergic mucin," or thick, inspissated mucus-containing degranulating eosinophils and fungal hyphae. Fungal colonization may also cause similar symptoms as those seen in CRS. In contrast, invasive fungal sinusitis typically occurs in immunocompromised hosts and can be rapidly progressive or indolent. (See  <a class="medical medical_review" href="/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis"</a> and  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">ANTIMICROBIAL THERAPY</span></p><p class="headingAnchor" id="H2802565358"><span class="h2">Uncertain role of systemic antibiotics</span><span class="headingEndMark"> — </span>The primary focus of medical management of CRS is to control inflammation that predisposes to obstruction and thus promote sinus drainage. Antibiotics are not a routine component of CRS management; data informing the benefit of antibiotics in CRS are limited, and there is no high-quality evidence to support their use. The decision to use antibiotics in patients with CRS should thus weigh the uncertain benefit against their known adverse effects and the risk of selection for bacterial resistance [<a href="#rid62">62</a>]. We reserve antibiotics for situations when bacterial infection is suspected; however, infection complicating CRS can be difficult to establish, and so practice varies. Some experts, including an editor of this topic, only use antibiotic therapy for CRS in the setting of an acute flare (eg, sudden worsening of symptoms). Other experts, including the author of this topic, also use antibiotics in situations when infection is possible and cannot be excluded, such as CRS without nasal polyposis that does not respond to several months of topical glucocorticoids. Further discussion on use of antibiotic therapy for CRS is found elsewhere. (See  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>Limited data do not demonstrate an obvious effect of antibiotics in CRS. A 2016 systematic review identified only five randomized trials (totaling nearly 300 participants) that compared antibiotic therapy with placebo or other medical interventions, the quality of most of the evidence was deemed low, and there was not a clear benefit of antibiotics [<a href="#rid63">63</a>]. A 2015 systematic review identified one small randomized trial comparing a short course of antibiotics with placebo; in patients with CRS with polyps, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for three weeks was associated with decreased polyp size post-treatment compared with placebo, but the only symptom improvement measure associated with doxycycline was a temporary reduction in postnasal drip compared with placebo [<a href="#rid64">64,65</a>]. </p><p>The evidence evaluating long-term, low-dose macrolide therapy as an anti-inflammatory strategy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis", section on 'Extended course of a macrolide antibiotic'</a>.)</p><p class="headingAnchor" id="H680941466"><span class="h2">Empiric regimen selection</span><span class="headingEndMark"> — </span>When antibiotic therapy is used as a component of medical management of CRS, we favor obtaining sinus specimens for microbiology to inform the regimen choice (see <a class="local">'Tailoring the regimen to culture results'</a> below). However, the initial regimen can be selected empirically and subsequently adjusted once cultures and susceptibility testing are available. Regimens for CRS are generally oral, since it is primarily an outpatient disease. We suggest a regimen that provides coverage against anaerobic bacteria (<em>F. nucleatum</em>, pigmented <em>Prevotella</em> spp, <em>Porphyromonas</em> spp, and <em>Peptostreptococcus </em>spp) as well as streptococci and <em>S. aureus. H. influenzae</em> and <em>M. catarrhalis</em> are rarely isolated in CRS but can be seen in acute exacerbations, and so we favor coverage of these as well, if possible. </p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, we suggest <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (in children 45 mg/kg per day divided every 12 hours; in adults 500 mg three times daily, or 875 mg twice daily, or two 1000 mg extended-release tablets twice daily) as the first-line regimen for most patients when antibiotic therapy is warranted for CRS. </p><p></p><p>Alternative regimens may be warranted in certain situations: </p><p class="bulletIndent1"><span class="glyph">●</span>For penicillin-allergic patients, we suggest monotherapy with <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (in children 20 to 40 mg/kg per day orally divided every six to eight hours; in adults 300 mg four times daily or 450 mg three times daily). Although clindamycin does not cover <em>H. influenzae,</em> <em>M. catarrhalis</em>, or other gram-negative bacilli, we favor it as a simple single agent regimen for an initial empiric regimen with the understanding that it may need to be modified if the patient does not respond. <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> is an alternative single-agent regimen that covers aerobic and anaerobic organisms, but it is used primarily in adults (400 mg once daily) as it has not been well studied in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a history of nasal methicillin-resistant <em>S. aureus </em>(MRSA) colonization or MRSA infection, we also suggest monotherapy with <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, as long as the prior MRSA isolate was not known to be clindamycin resistant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with immunocompromising conditions, cystic fibrosis, or diabetes mellitus may also warrant coverage against <em>P. aeruginosa,</em> which can be achieved with <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> (750 mg daily in adults) plus <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>. </p><p></p><p>Other regimens that provide aerobic and anaerobic coverage consist of two drugs. These regimens are more cumbersome and are usually reserved for patients who cannot take one of the single-drug regimens. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a> <strong>plus</strong> one of the following: <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a> axetil, <a class="drug drug_general" data-topicid="8602" href="/d/drug information/8602.html" rel="external">cefdinir</a>, <a class="drug drug_general" data-topicid="9224" href="/d/drug information/9224.html" rel="external">cefpodoxime</a> proxetil, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>. If MRSA coverage is needed, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> could be used with metronidazole.</p><p></p><p>Among the options, antibiotic selection further depends upon other factors, including history of drug allergies and cost of therapy. In addition, if antibiotics have been given over the past three months, a different class of antibiotics should be used. Before choosing a fluoroquinolone (such as <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>), clinicians and patients should be aware of the potential for adverse effects and the recommendations to avoid their use for uncomplicated infections when other alternatives are appropriate. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Restriction of use for uncomplicated infections'</a>.)</p><p>Our approach to antibiotic selection is primarily based on the understanding of the microbiology of CRS. Data from trials have not suggested a higher likelihood of clinical cure with particular antimicrobial regimens over others [<a href="#rid66">66-69</a>], even though observational studies have suggested that antibiotics with anaerobic coverage might result in greater cure rates [<a href="#rid16">16,70</a>]. Nevertheless, in one randomized trial of more than 200 adults with CRS, the relapse rate was higher with <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a> compared with <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (7 versus 0 percent), suggesting that including anaerobic coverage may be important for preventing relapse [<a href="#rid66">66</a>].</p><p>Topical or systemic antifungal therapy should not be used as empiric therapy in patients with CRS, as it does not appear to be effective [<a href="#rid71">71,72</a>]. The role of antifungal therapy for patients with allergic fungal rhinosinusitis or invasive fungal rhinosinusitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis", section on 'Therapies of uncertain benefit'</a> and  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Invasive fungal sinusitis'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Tailoring the regimen to culture results</span><span class="headingEndMark"> — </span>We favor obtaining sinus specimens for microbiologic testing so that the empirically selected antibiotic regimen can be tailored accordingly. In particular, we favor obtaining sinus specimens for patients with severely immunocompromising conditions or persistent or worsening infection despite appropriate initial antibiotics (eg, no substantial improvement after five to seven days of treatment), as pathogens beyond the typical microbiology are more likely in these cases. </p><p>Specimens should be obtained directly from the involved sinus cavity, usually by an otolaryngology specialist. An endoscopic approach to obtain culture specimens is a commonly used alternative to sinus puncture [<a href="#rid73">73</a>]. However, specimens obtained by endoscopy can become contaminated with nasal flora [<a href="#rid74">74</a>]. The sinus specimens should be submitted for culture for aerobic and anaerobic bacteria as well as fungi. Proper collection, transport, and plating are important for optimizing culture yield. </p><p>Once cultures are available, we tailor the regimen to ensure activity against isolated organisms that would be resistant to the empirically chosen regimen. We generally suggest <strong>not</strong> narrowing the empiric regimen to cover only the organism cultured because certain bacteria, such as anaerobes, may be difficult to isolate.</p><p>For patients who have a fungal organism isolated on sinus cultures, the approach is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Invasive fungal sinusitis'</a>.)</p><p class="headingAnchor" id="H2024741437"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of antimicrobial therapy is uncertain.</p><p>When antibiotics are used for acute exacerbations of CRS, seven days is a reasonable duration. In patients who are slow to respond, the author of this topic sometimes uses longer therapy (eg, up to 21 days). </p><p>If antibiotics are used for other situations when an infection is suspected and cannot be ruled out (eg, symptoms refractory to other anti-inflammatory measures), antibiotics are often given for two to four weeks. As above, use of antibiotics for this purpose is not universally endorsed. (See <a class="local">'Uncertain role of systemic antibiotics'</a> above.)</p><p>The evidence to support the duration recommendation is limited; only low-quality evidence supports the efficacy of antibiotics in the treatment of CRS, as above, and the duration of therapy has not been studied prospectively. Decisions on antibiotic duration in individual patients should weigh the uncertain benefit against the potential for adverse effects with prolonged therapy.</p><p class="headingAnchor" id="H81808444"><span class="h2">Limited role for other antibiotic routes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral therapy</strong> – Even when antibiotics are warranted for CRS, parenteral therapy is rarely needed. Parenteral antibiotics may be indicated in patients who are seriously ill or perioperatively. Sinus cultures should be obtained from patients requiring parenteral therapy.</p><p></p><p class="bulletIndent1">Parenteral antibiotics effective against both anaerobes and aerobes include <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, and the second-generation cephalosporins (<a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> and <a class="drug drug_general" data-topicid="9222" href="/d/drug information/9222.html" rel="external">cefotetan</a>). A parenteral agent with aerobic activity (eg, a third-generation cephalosporin such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) may also be given in combination with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> to cover anaerobes. The absorption of oral metronidazole is excellent, so metronidazole should only be given parenterally if the patient is unable to take oral medications. The selection among parenteral options should be informed by available culture results. </p><p></p><p class="bulletIndent1">If <em>P. aeruginosa</em> or MRSA is suspected, active parenteral options are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Intravenous antibiotics'</a> and  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Preferred agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antibiotic therapies</strong> – Data supporting the use of topic antibiotics are limited, and we do not routinely use them in patients with CRS. However, the author of this topic has used topical antibiotics (eg, <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> ointment in <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> nasal irrigations) in select patients with refractory CRS with documented infection that has not responded to multiple courses of oral antibiotics. When used, the author suggests topical antibiotics once or twice daily for up to four weeks. </p><p></p><p class="bulletIndent1">Topical antibiotic therapies are thought to deliver a high concentration of antibiotics to the diseased sinonasal mucosa. Studies do not demonstrate clear benefit of topical antibiotics, although there may be short-term benefit for select patients [<a href="#rid64">64,73,75-78</a>]. One review identified three randomized trials that showed no clinical effect compared with placebo and one randomized trial that demonstrated short-term symptom improvement with <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> in patients with <em>S. aureus</em> growth on sinus cultures [<a href="#rid64">64</a>]. In that trial, however, clinical and microbiologic effects were not maintained two months after therapy. Topical mupirocin has also been associated with a decline in the number of gram-positive bacteria and an increase in potential pathogenic gram-negative bacteria and <em>Corynebacterium</em> [<a href="#rid79">79</a>]. Another systematic review noted low-quality evidence of benefit for patients with refractory CRS who have undergone sinus surgery and receive culture-directed topical antibiotic therapy [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nebulized antimicrobials</strong> – Data supporting the use of nebulized antimicrobials are limited, and we do not routinely use them for patients with CRS. However, the author of this topic has used them in select patients with refractory CRS with documented infection that has not responded to multiple courses of oral antibiotics. </p><p></p><p class="bulletIndent1">The use of nebulized antimicrobials is also generally reserved for postsurgical patients, in whom there are wider than usual openings into the sinus cavities [<a href="#rid80">80</a>]. Even in this population, data informing the effect of nebulized antimicrobials are limited to small observational studies. In a retrospective study of 42 patients with CRS, previous sinus surgery, and an acute infection, those who chose nebulized antibiotic therapy had a longer infection-free period than those who chose systemic antibiotics [<a href="#rid81">81</a>]. In another observational study, three to six weeks of nebulized antibiotics were safe and associated with improved symptoms in 34 of 41 (83 percent) of patients with CRS and recurrent acute infections after previous surgery [<a href="#rid82">82</a>]. Nebulized delivery may also offer potential benefits over nasal sprays in the management of CRS patients, as nebulization allows for small particles to be distributed over a wider area of sinonasal mucosa [<a href="#rid83">83,84</a>]. However, further studies are needed to define the role of nebulized antimicrobials in the management of CRS.</p><p></p><p class="headingAnchor" id="H3828452945"><span class="h1">OTHER COMPONENTS OF THERAPY</span><span class="headingEndMark"> — </span>The goal of medical therapy for CRS is to promote sinus drainage, reduce chronic inflammation, and eradicate infecting pathogens. Antimicrobial therapy is just one potential component of a comprehensive medical approach, which also includes topical or systemic glucocorticoids and nasal irrigation. These other components of therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a>.)</p><p>When these measures fail, the patient should be referred to an otolaryngologist for consideration of sinus surgery. (See  <a class="medical medical_review" href="/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Surgical management'</a> and  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis", section on 'Functional endoscopic sinus surgery'</a>.)</p><p>Patients with concurrent odontogenic infections should be evaluated and treated by a dentist. Antimicrobial therapy is only an adjuvant to dental management directed at resolving the odontogenic source. (See  <a class="medical medical_review" href="/d/html/3416.html" rel="external">"Complications, diagnosis, and treatment of odontogenic infections", section on 'Therapeutic considerations'</a>.)</p><p class="headingAnchor" id="H162905720"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86637.html" rel="external">"Patient education: Chronic sinusitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/378.html" rel="external">"Patient education: Chronic rhinosinusitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> − Chronic rhinosinusitis (CRS) is defined as an inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer, despite attempts at medical management. The diagnostic criteria for CRS are discussed separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evolution of bacterial flora</strong> − The microbiology evolves through several phases. The early phase (acute rhinosinusitis) is usually caused by a viral infection but may be followed by an aerobic bacterial infection in a minority of patients. With CRS, colonizing anaerobic oropharyngeal flora and aerobes such as <em>Staphylococcus aureus</em> become predominant over time. (See <a class="local">'Evolution of bacterial flora'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fungi</strong> − Fungi may cause allergic fungal rhinosinusitis, colonization of the sinuses, and invasive fungal sinusitis. (See <a class="local">'Fungi'</a> above and  <a class="medical medical_review" href="/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis"</a> and  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial therapy</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of antibiotics</strong> − Antibiotics are not a routine component of CRS management, and there is no high-quality evidence to support their use. We reserve antibiotics for situations when bacterial infection is suspected; however, infection complicating CRS can be difficult to establish. Some experts, including an editor of this topic, only use antibiotic therapy for CRS in the setting of an acute flare (eg, sudden worsening of symptoms). Other experts, including the author of this topic, also use antibiotics in situations when infection is possible and cannot be excluded, such as CRS that does not respond to several months of topical glucocorticoids. (See <a class="local">'Uncertain role of systemic antibiotics'</a> above and  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric regimen selection</strong> − A number of antimicrobial regimens are available to treat CRS. Given that most of these infections are polymicrobial and many include anaerobes, we suggest <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> as the first-line regimen for most patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatives include <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> and combinations of <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> with a second- or third-generation cephalosporin, a macrolide, or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. (See <a class="local">'Empiric regimen selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tailoring regimen to culture results</strong> − Sinus culture should be obtained in patients to inform the adequacy of the empiric regimen. We broaden therapy to include coverage for isolated pathogens that are resistant to the empiric regimen. We generally suggest <strong>not</strong> narrowing the regimen to cover only the organisms cultured because certain bacteria, such as anaerobes, may be difficult to isolate (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Tailoring the regimen to culture results'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> − Therapy is usually given for seven days for acute exacerbations of CRS, but may warrant a longer duration in some cases. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brook I. Aerobic and anaerobic bacterial flora of normal maxillary sinuses. Laryngoscope 1981; 91:372.</a></li><li><a class="nounderline abstract_t">Albu S, Florian IS. Bacteriology of normal frontal sinuses. Am J Otolaryngol 2013; 34:327.</a></li><li><a class="nounderline abstract_t">Ramakrishnan VR, Hauser LJ, Feazel LM, et al. Sinus microbiota varies among chronic rhinosinusitis phenotypes and predicts surgical outcome. J Allergy Clin Immunol 2015; 136:334.</a></li><li><a class="nounderline abstract_t">Aurora R, Chatterjee D, Hentzleman J, et al. Contrasting the microbiomes from healthy volunteers and patients with chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2013; 139:1328.</a></li><li><a class="nounderline abstract_t">Danielsen KA, Eskeland O, Fridrich-Aas K, et al. Bacterial biofilms in patients with chronic rhinosinusitis: a confocal scanning laser microscopy study. Rhinology 2014; 52:150.</a></li><li><a class="nounderline abstract_t">Zhang Z, Adappa ND, Chiu AG, et al. Biofilm-forming bacteria and quality of life improvement after sinus surgery. Int Forum Allergy Rhinol 2015; 5:643.</a></li><li><a class="nounderline abstract_t">Sande MA, Gwaltney JM. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin Infect Dis 2004; 39 Suppl 3:S151.</a></li><li><a class="nounderline abstract_t">Brook I. Acute and chronic bacterial sinusitis. Infect Dis Clin North Am 2007; 21:427.</a></li><li><a class="nounderline abstract_t">Bhattacharyya N. The role of infection in chronic rhinosinusitis. Curr Allergy Asthma Rep 2002; 2:500.</a></li><li><a class="nounderline abstract_t">Brook I. Bacteriologic features of chronic sinusitis in children. JAMA 1981; 246:967.</a></li><li><a class="nounderline abstract_t">Brook I. Bacteriology of chronic maxillary sinusitis in adults. Ann Otol Rhinol Laryngol 1989; 98:426.</a></li><li><a class="nounderline abstract_t">Brook I. Bacteriology of acute and chronic frontal sinusitis. Arch Otolaryngol Head Neck Surg 2002; 128:583.</a></li><li><a class="nounderline abstract_t">Brook I. Bacteriology of acute and chronic sphenoid sinusitis. Ann Otol Rhinol Laryngol 2002; 111:1002.</a></li><li><a class="nounderline abstract_t">Brook I. Bacteriology of acute and chronic ethmoid sinusitis. J Clin Microbiol 2005; 43:3479.</a></li><li><a class="nounderline abstract_t">Nord CE. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 1995; 20:1512.</a></li><li><a class="nounderline abstract_t">Brook I, Thompson DH, Frazier EH. Microbiology and management of chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1994; 120:1317.</a></li><li><a class="nounderline abstract_t">Finegold SM, Flynn MJ, Rose FV, et al. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis 2002; 35:428.</a></li><li><a class="nounderline abstract_t">Brook I, Yocum P, Shah K. Aerobic and anaerobic bacteriology of concurrent chronic otitis media with effusion and chronic sinusitis in children. Arch Otolaryngol Head Neck Surg 2000; 126:174.</a></li><li><a class="nounderline abstract_t">Erkan M, Ozcan M, Arslan S, et al. Bacteriology of antrum in children with chronic maxillary sinusitis. Scand J Infect Dis 1996; 28:283.</a></li><li><a class="nounderline abstract_t">Frederick J, Braude AI. Anaerobic infection of the paranasal sinuses. N Engl J Med 1974; 290:135.</a></li><li><a class="nounderline abstract_t">Van Cauwenberge P, Verschraegen G, Van Renterghem L. Bacteriological findings in sinusitis (1963-1975). Scand J Infect Dis Suppl 1976; :72.</a></li><li><a class="nounderline abstract_t">Karma P, Jokipii L, Sipilä P, et al. Bacteria in chronic maxillary sinusitis. Arch Otolaryngol 1979; 105:386.</a></li><li><a class="nounderline abstract_t">Berg O, Carenfelt C, Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis 1988; 20:511.</a></li><li><a class="nounderline abstract_t">Erkan M, Aslan T, Ozcan M, Koç N. Bacteriology of antrum in adults with chronic maxillary sinusitis. Laryngoscope 1994; 104:321.</a></li><li><a class="nounderline abstract_t">Klossek JM, Dubreuil L, Richet H, et al. Bacteriology of chronic purulent secretions in chronic rhinosinusitis. J Laryngol Otol 1998; 112:1162.</a></li><li><a class="nounderline abstract_t">Brook I, Frazier EH, Foote PA. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol 1996; 45:372.</a></li><li><a class="nounderline abstract_t">Lal D, Keim P, Delisle J, et al. Mapping and comparing bacterial microbiota in the sinonasal cavity of healthy, allergic rhinitis, and chronic rhinosinusitis subjects. Int Forum Allergy Rhinol 2017; 7:561.</a></li><li><a class="nounderline abstract_t">Brook I, Yocum P. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with chronic maxillary sinusitis. Ann Otol Rhinol Laryngol 1999; 108:293.</a></li><li><a class="nounderline abstract_t">Aust R, Drettner B. Oxygen tension in the human maxillary sinus under normal and pathological conditions. Acta Otolaryngol 1974; 78:264.</a></li><li><a class="nounderline abstract_t">Carenfelt C, Lundberg C. Purulent and non-purulent maxillary sinus secretions with respect to pO2, pCO2 and pH. Acta Otolaryngol 1977; 84:138.</a></li><li><a class="nounderline abstract_t">Brook I, Myhal LA, Dorsey CH. Encapsulation and pilus formation of Bacteroides spp. in normal flora abscesses and blood. J Infect 1992; 25:251.</a></li><li><a class="nounderline abstract_t">Brook I. Role of encapsulated anaerobic bacteria in synergistic infections. Crit Rev Microbiol 1987; 14:171.</a></li><li><a class="nounderline abstract_t">Doyle PW, Woodham JD. Evaluation of the microbiology of chronic ethmoid sinusitis. J Clin Microbiol 1991; 29:2396.</a></li><li><a class="nounderline abstract_t">Shapiro ED, Milmoe GJ, Wald ER, et al. Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J Infect Dis 1982; 146:589.</a></li><li><a class="nounderline abstract_t">Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol 1998; 12:233.</a></li><li><a class="nounderline abstract_t">Bhattacharyya N, Kepnes LJ. The microbiology of recurrent rhinosinusitis after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 1999; 125:1117.</a></li><li><a class="nounderline abstract_t">Brook I. Microbiology of acute and chronic maxillary sinusitis associated with an odontogenic origin. Laryngoscope 2005; 115:823.</a></li><li><a class="nounderline abstract_t">Decker CF. Sinusitis in the Immunocompromised Host. Curr Infect Dis Rep 1999; 1:27.</a></li><li><a class="nounderline abstract_t">Hsu J, Lanza DC, Kennedy DW. Antimicrobial resistance in bacterial chronic sinusitis. Am J Rhinol 1998; 12:243.</a></li><li><a class="nounderline abstract_t">Brook I, Frazier EH. Correlation between microbiology and previous sinus surgery in patients with chronic maxillary sinusitis. Ann Otol Rhinol Laryngol 2001; 110:148.</a></li><li><a class="nounderline abstract_t">Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope 2006; 116:288.</a></li><li><a class="nounderline abstract_t">Manarey CR, Anand VK, Huang C. Incidence of methicillin-resistant Staphylococcus aureus causing chronic rhinosinusitis. Laryngoscope 2004; 114:939.</a></li><li><a class="nounderline abstract_t">Brook I, Foote PA, Hausfeld JN. Increase in the frequency of recovery of meticillin-resistant Staphylococcus aureus in acute and chronic maxillary sinusitis. J Med Microbiol 2008; 57:1015.</a></li><li><a class="nounderline abstract_t">Becker SS, Russell PT, Duncavage JA, Creech CB. Current issues in the management of sinonasal methicillin-resistant Staphylococcus aureus. Curr Opin Otolaryngol Head Neck Surg 2009; 17:2.</a></li><li><a class="nounderline abstract_t">Lin J, Xu P, Peng Y, et al. Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China. J Diabetes Investig 2017; 8:383.</a></li><li><a class="nounderline abstract_t">Zhang Z, Adappa ND, Lautenbach E, et al. The effect of diabetes mellitus on chronic rhinosinusitis and sinus surgery outcome. Int Forum Allergy Rhinol 2014; 4:315.</a></li><li><a class="nounderline abstract_t">Jiang RS, Hsu CY, Jang JW. Bacteriology of the maxillary and ethmoid sinuses in chronic sinusitis. J Laryngol Otol 1998; 112:845.</a></li><li><a class="nounderline abstract_t">Brook I, Frazier EH. Bacteriology of chronic maxillary sinusitis associated with nasal polyposis. J Med Microbiol 2005; 54:595.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee K, Yoo JB, et al. Bacteriological findings and antimicrobial susceptibility in chronic sinusitis with nasal polyp. Acta Otolaryngol 2006; 126:489.</a></li><li><a class="nounderline abstract_t">Niederfuhr A, Kirsche H, Riechelmann H, Wellinghausen N. The bacteriology of chronic rhinosinusitis with and without nasal polyps. Arch Otolaryngol Head Neck Surg 2009; 135:131.</a></li><li><a class="nounderline abstract_t">Brook I, Foote PA, Frazier EH. Microbiology of acute exacerbation of chronic sinusitis. Ann Otol Rhinol Laryngol 2005; 114:573.</a></li><li><a class="nounderline abstract_t">Mehra P, Jeong D. Maxillary sinusitis of odontogenic origin. Curr Infect Dis Rep 2008; 10:205.</a></li><li><a class="nounderline abstract_t">Saibene AM, Vassena C, Pipolo C, et al. Odontogenic and rhinogenic chronic sinusitis: a modern microbiological comparison. Int Forum Allergy Rhinol 2016; 6:41.</a></li><li><a class="nounderline abstract_t">Brook I, Frazier EH, Gher ME Jr. Microbiology of periapical abscesses and associated maxillary sinusitis. J Periodontol 1996; 67:608.</a></li><li><a class="nounderline abstract_t">Gillespie MB, O'Malley BW Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg 1998; 124:520.</a></li><li><a class="nounderline abstract_t">Silveira MLC, Anselmo-Lima WT, Faria FM, et al. Impact of early detection of acute invasive fungal rhinosinusitis in immunocompromised patients. BMC Infect Dis 2019; 19:310.</a></li><li><a class="nounderline abstract_t">Godofsky EW, Zinreich J, Armstrong M, et al. Sinusitis in HIV-infected patients: a clinical and radiographic review. Am J Med 1992; 93:163.</a></li><li><a class="nounderline abstract_t">Del Borgo C, Del Forno A, Ottaviani F, Fantoni M. Sinusitis in HIV-infected patients. J Chemother 1997; 9:83.</a></li><li><a class="nounderline abstract_t">Dunand VA, Hammer SM, Rossi R, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis 1997; 25:267.</a></li><li class="breakAll">Finegold SM. Anaerobic bacteria in human disease, Academic Press Inc, Orlando, FL 1977.</li><li><a class="nounderline abstract_t">Brook I. Microbiology of intracranial abscesses and their associated sinusitis. Arch Otolaryngol Head Neck Surg 2005; 131:1017.</a></li><li><a class="nounderline abstract_t">Kingdom TT, Swain RE Jr. The microbiology and antimicrobial resistance patterns in chronic rhinosinusitis. Am J Otolaryngol 2004; 25:323.</a></li><li><a class="nounderline abstract_t">Head K, Chong LY, Piromchai P, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011994.</a></li><li><a class="nounderline abstract_t">Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. JAMA 2015; 314:926.</a></li><li><a class="nounderline abstract_t">Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol 2010; 125:1069.</a></li><li><a class="nounderline abstract_t">Namyslowski G, Misiolek M, Czecior E, et al. Comparison of the efficacy and tolerability of amoxycillin/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother 2002; 14:508.</a></li><li><a class="nounderline abstract_t">Legent F, Bordure P, Beauvillain C, Berche P. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy 1994; 40 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">Husfeldt P, Egede F, Nielsen PB. Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin. Eur Arch Otorhinolaryngol 1993; 250 Suppl 1:S23.</a></li><li><a class="nounderline abstract_t">Dubin MG, Kuhn FA, Melroy CT. Radiographic resolution of chronic rhinosinusitis without polyposis after 6 weeks vs 3 weeks of oral antibiotics. Ann Allergy Asthma Immunol 2007; 98:32.</a></li><li><a class="nounderline abstract_t">Brook I, Yocum P. Antimicrobial management of chronic sinusitis in children. J Laryngol Otol 1995; 109:1159.</a></li><li><a class="nounderline abstract_t">Sacks PL 4th, Harvey RJ, Rimmer J, et al. Antifungal therapy in the treatment of chronic rhinosinusitis: a meta-analysis. Am J Rhinol Allergy 2012; 26:141.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015; 152:S1.</a></li><li><a class="nounderline abstract_t">Brook I. Beta-lactamase-producing bacteria in head and neck infection. Laryngoscope 1988; 98:428.</a></li><li><a class="nounderline abstract_t">Thanasumpun T, Batra PS. Endoscopically-derived bacterial cultures in chronic rhinosinusitis: A systematic review. Am J Otolaryngol 2015; 36:686.</a></li><li><a class="nounderline abstract_t">Luk LJ, DelGaudio JM. Topical Drug Therapies for Chronic Rhinosinusitis. Otolaryngol Clin North Am 2017; 50:533.</a></li><li><a class="nounderline abstract_t">Jervis-Bardy J, Boase S, Psaltis A, et al. A randomized trial of mupirocin sinonasal rinses versus saline in surgically recalcitrant staphylococcal chronic rhinosinusitis. Laryngoscope 2012; 122:2148.</a></li><li><a class="nounderline abstract_t">Jervis-Bardy J, Wormald PJ. Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery. Int Forum Allergy Rhinol 2012; 2:111.</a></li><li><a class="nounderline abstract_t">Lee JT, Chiu AG. Topical anti-infective sinonasal irrigations: update and literature review. Am J Rhinol Allergy 2014; 28:29.</a></li><li><a class="nounderline abstract_t">Carr TF, Hill JL, Chiu A, Chang EH. Alteration in Bacterial Culture After Treatment With Topical Mupirocin for Recalcitrant Chronic Rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2016; 142:138.</a></li><li><a class="nounderline abstract_t">Leonard DW, Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. Laryngoscope 1999; 109:668.</a></li><li><a class="nounderline abstract_t">Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg 2002; 127:558.</a></li><li><a class="nounderline abstract_t">Scheinberg PA, Otsuji A. Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis. Ear Nose Throat J 2002; 81:648.</a></li><li class="breakAll">Suman JD, Laube BL, Dalby R. Nasal nebulizers versus aqueous nasal spray pumps: A comparison of deposition patterns in human volunteers. In: Respiratory Drug Delivery VI, Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL 1998. p.211.</li><li><a class="nounderline abstract_t">Durand M, Rusch P, Granjon D, et al. Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. J Aerosol Med 2001; 14:83.</a></li></ol></div><div id="topicVersionRevision">Topic 3412 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7464398" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aerobic and anaerobic bacterial flora of normal maxillary sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375589" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bacteriology of normal frontal sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819063" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sinus microbiota varies among chronic rhinosinusitis phenotypes and predicts surgical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24177790" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contrasting the microbiomes from healthy volunteers and patients with chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932627" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bacterial biofilms in patients with chronic rhinosinusitis: a confocal scanning laser microscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25763837" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Biofilm-forming bacteria and quality of life improvement after sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546110" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute community-acquired bacterial sinusitis: continuing challenges and current management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17561077" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute and chronic bacterial sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359121" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of infection in chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6973029" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bacteriologic features of chronic sinusitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729825" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bacteriology of chronic maxillary sinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12003592" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bacteriology of acute and chronic frontal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12450174" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bacteriology of acute and chronic sphenoid sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000483" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bacteriology of acute and chronic ethmoid sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7548501" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980894" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Microbiology and management of chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145727" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680868" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aerobic and anaerobic bacteriology of concurrent chronic otitis media with effusion and chronic sinusitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8863363" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bacteriology of antrum in children with chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4148564" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anaerobic infection of the paranasal sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1070150" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bacteriological findings in sinusitis (1963-1975).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313206" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bacteria in chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3222668" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127189" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bacteriology of antrum in adults with chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209612" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bacteriology of chronic purulent secretions in chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918954" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Microbiology of the transition from acute to chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28481057" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mapping and comparing bacterial microbiota in the sinonasal cavity of healthy, allergic rhinitis, and chronic rhinosinusitis subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086624" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432751" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oxygen tension in the human maxillary sinus under normal and pathological conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Purulent and non-purulent maxillary sinus secretions with respect to pO2, pCO2 and pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361937" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Encapsulation and pilus formation of Bacteroides spp. in normal flora abscesses and blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3556018" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Role of encapsulated anaerobic bacteria in synergistic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1774242" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evaluation of the microbiology of chronic ethmoid sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6813383" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bacteriology of the maxillary sinuses in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740915" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endoscopically guided cultures in chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522504" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The microbiology of recurrent rhinosinusitis after endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867647" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Microbiology of acute and chronic maxillary sinusitis associated with an odontogenic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095763" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sinusitis in the Immunocompromised Host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740916" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antimicrobial resistance in bacterial chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11219522" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Correlation between microbiology and previous sinus surgery in patients with chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467721" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126760" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence of methicillin-resistant Staphylococcus aureus causing chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628504" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Increase in the frequency of recovery of meticillin-resistant Staphylococcus aureus in acute and chronic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225299" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Current issues in the management of sinonasal methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808480" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415555" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of diabetes mellitus on chronic rhinosinusitis and sinus surgery outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876374" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bacteriology of the maxillary and ethmoid sinuses in chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888469" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bacteriology of chronic maxillary sinusitis associated with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698698" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bacteriological findings and antimicrobial susceptibility in chronic sinusitis with nasal polyp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221239" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The bacteriology of chronic rhinosinusitis with and without nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134356" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Microbiology of acute exacerbation of chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18510882" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Maxillary sinusitis of odontogenic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26345711" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Odontogenic and rhinogenic chronic sinusitis: a modern microbiological comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794972" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Microbiology of periapical abscesses and associated maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9604977" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953465" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of early detection of acute invasive fungal rhinosinusitis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497012" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sinusitis in HIV-infected patients: a clinical and radiographic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176744" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sinusitis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332522" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332522" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301376" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Microbiology of intracranial abscesses and their associated sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334396" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The microbiology and antimicrobial resistance patterns in chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113482" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Systemic and topical antibiotics for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26325561" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Medical Therapies for Adult Chronic Sinusitis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451040" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Oral steroids and doxycycline: two different approaches to treat nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12462431" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of the efficacy and tolerability of amoxycillin/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7805431" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476582" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17225717" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Radiographic resolution of chronic rhinosinusitis without polyposis after 6 weeks vs 3 weeks of oral antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8551146" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antimicrobial management of chronic sinusitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487292" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Antifungal therapy in the treatment of chronic rhinosinusitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832968" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical practice guideline (update): adult sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3258396" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Beta-lactamase-producing bacteria in head and neck infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964173" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Endoscopically-derived bacterial cultures in chronic rhinosinusitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28389018" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Topical Drug Therapies for Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22865576" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A randomized trial of mupirocin sinonasal rinses versus saline in surgically recalcitrant staphylococcal chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22170745" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717876" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Topical anti-infective sinonasal irrigations: update and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720201" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Alteration in Bacterial Culture After Treatment With Topical Mupirocin for Recalcitrant Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201762" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Topical antibiotic therapy for recalcitrant sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12501108" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Use of nebulized antibiotics for acute infections in chronic sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353442" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353442" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495489" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
